BioSpace News Archive

Keynote at Drug Discovery Innovation Programme and Company Presentation at JMP Securities Life Sciences Conference

New investment fuels continued innovation, market expansion, and necessary developments for more complex, higher-value care

TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that it has expanded its recently formed Scientific Advisory Board (SAB) and will support the continued clinical development of the Company’s transformative, non-genetically engineered, multi-antigen T cell therapy platform.

Check-Cap Ltd. a clinical stage medical diagnostics company engaged in the development of C-Scan®, today announced that the results of its multicenter clinical study that examined C-Scan safety and efficacy (compared to FIT and colonoscopy) for polyp detection confirmed by ensuing colonoscopy.

Trianni, Inc. (“TRIANNI”) and Antibody Solutions jointly announced today that Antibody Solutions has entered into a license agreement with TRIANNI for use of The Trianni Mouse™, a best-in-class fully humanized transgenic mouse platform, to support its therapeutic antibody discovery programs.

NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”) a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the “Company”), filed its quarterly report for its third quarter of financial year 2018.

AnaBios is pleased to announce the recent hire of Chris Mathes, Ph.D., MBA, as Chief Commercial Officer.

Conference call to be held May 30, 2018 at 4:30 p.m. Eastern time

Pliant Therapeutics, Inc. today presents at the American Thoracic Society 2018 International Conference a new approach to identify novel biomarkers to improve diagnosis, selection and assessment of treatments for Idiopathic Pulmonary Fibrosis (IPF)

Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Allergan plc (NYSE: AGN) has exercised its option to acquire drug candidate AGN-241751, an oral small-molecule N-methyl-D-aspartate (NMDA) receptor modulator